Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

45.85 +0.70 (+1.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
News headline image
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program ↗
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue. 
Via Benzinga
Topics Lawsuit
News headline image
Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales ↗
Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and commercial rights shift to Sanofi. 
Via Benzinga
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca ↗
Via Stocktwits
News headline image
What's Driving the Market Sentiment Around Sanofi? ↗
 
Via Benzinga
News headline image
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts ↗
These biotech businesses look compelling for very different reasons. 
Via The Motley Fool
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients ↗
FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes. 
Via Benzinga
News headline image
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines ↗
Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals. 
Via Benzinga
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗
Via Stocktwits
Topics Government
News headline image
Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount ↗
Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential contrarian discount. 
Via Benzinga
Topics Earnings
News headline image
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales ↗
Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward. 
Via Benzinga
News headline image
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades. ↗
You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save. 
Via The Motley Fool
Topics Artificial Intelligence Retirement
News headline image
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel ↗
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline. 
Via Benzinga
News headline image
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates ↗
Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose preclinical studies. 
Via Benzinga
News headline image
Why Thermo Fischer Stock Is Rising Wednesday ↗
Thermo Fisher beat Q2 estimates, raised its 2025 guidance, and announced a CFO transition as easing tariffs support an improved outlook. 
Via Benzinga
Topics World Trade
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Humana Moves To Cut Prior Authorization Delays, Streamline Care Approvals ↗
Humana will cut prior authorizations, launch a gold card program, and speed up electronic approvals to improve care access and transparency by 2026. 
Via Benzinga
News headline image
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
News headline image
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy ↗
Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults ↗
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony ↗
Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge. 
Via Benzinga
Topics Lawsuit
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focus ↗
While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%. 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst ↗
Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025. 
Via Benzinga
News headline image
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot ↗
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot. 
Via Investor's Business Daily
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma ↗
FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.